Sinopep-Allsino Biopharmaceutical Co Ltd.is a premier pharmaceutical company mainly focused the research and development (R&D), production, sales and technical services of peptide and small molecule drugs. Sinopep is a National High-tech and provincial science and technology enterprise, established in April 2009, located in the Lianyungang National Economic and Technological Development Zone. On May 20th, Sinopep-Allsino was listed on the STAR Market of Shanghai Stock Exchange (Stock Name/Code: Sinopep/ 688076). Currently we have more than 900 employees.
Through technological innovation, the company is committed to breaking through the technical bottleneck of drug R&D and production, building a whole industry chain from pharmaceutical intermediates, APIs to formulation, and providing green, low-cost, high-quality, and efficient pharmaceutical-related products and technical services for the worldwide partners.
R&D. As an innovation-driven company, Sinopep-Allsino constantly strengthens its capability of independent innovation. Every year, more than 10% if gross annual revenue was invested in R&D. There are three provincial-level R&D centers, namely, Sinopep Biology, Allsino and Simbospharm, and a R&D team with international technical level led by experts of national key talent and provincial talent plans. With more than 160 members, in wich 40 with master's degree or above, including 6 overseas returnees. The R&D center provides solid technical support for the business layout of the company's whole industry chain by integrating software and hardware conditions and realizing technology integration. In addition, Sinopep-Allsino has cooperated with Prof. Hartmut Michel, a German biochemist and Nobel Prize winner in chemistry, to set up a Nobel Prize workstation in accelerating the company's technological innovation. Sinopep-Allsino has 77 authorized patents, including 36 invention patents, and has established good cooperation with many universities and scientific research institutes
Production. Sinopep-Allsino has established two modern production bases in Lianyungang, Jiangsu Province and Jiande, Zhejiang Province, with the large-scale production capacity covering the two fields of peptides and small molecular chemicals, complying with international regulations and market standards, and covering the whole industrial chain of "advanced pharmaceutical intermediates-APIs-preparations". Hard capsules, tablets, freeze-dried powder injection, small volume injections and some APIs have passed the national GMP certification, and the quality system of peptide APIs has passed the US FDA's cGMP on-site inspection three times in 2014, 2016 and 2019. In the re-inspection in January 2019, Sinopep-Allsino successfully passed the "zero defect" ("NAI"), which laid a foundation for the company's products to enhance their competitiveness in the international market.
Marketing. Sinopep-Allsino adheres to the globle strategy, providing internationalized variety and business layout, talent team and production system construction, in order to improve the international competitiveness of the products and services. After years of development, the company has won the recognition of many world-renowned pharmaceutical enterprises by virtue of advanced R&D technology and high standard quality management system, and has established a long-term and stable cooperative relationship.
In the future, Sinopep-Allsino will contitue to follow the innovation-driven development mode, improve technological innovation ability, and eventually become an internationally renowned biopharmaceutical company with the peptide innovative drugs as the main body, blockbuster generic drugs and technical services as two wings, and with a R&D/production capacity of the whole pharmaceutical industry chain.
| Full name | Sinopep-Allsino Biopharmaceutical Co., Ltd. |
|---|---|
| Abbreviations | Sinopep |
| Code | 688076 |
| Founded | 2009-04-03 |
| Listing | 2021-05-20 |
| Domicile | Lianyungang, Jiangsu Province |
| Website | http://www.sinopep.com/ |
| ting.guo@sinopep.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Pharmaceutical manufacturing industry |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | RMB0.77 | RMB0.30 | RMB0.32 |
| R&D expenditure as a % of operating revenue | 11.83% | 13.71% | 16.26% |
| Operating Revenue | 566.87 | 371.53 | 255.53 |
| Net Income | 120.03 | 44.81 | 44.68 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 566.87 | 371.53 | 255.53 |
| Operating Costs | 445.76 | 318.29 | 225.18 |
| Operating Income | 143.82 | 49.58 | 31.44 |
| Pretax Income | 146.56 | 53.41 | 31.34 |
| Income Tax | 26.53 | 8.61 | -13.34 |
| Net Income | 120.03 | 44.81 | 44.68 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 487.91 | 293.73 | 357.67 |
| Non-current Assets-Total | 907.67 | 950.78 | 693.18 |
| Total Assets | 1,395.57 | 1,244.51 | 1,050.85 |
| Liabilities | |||
| Current Liabilities-Total | 382.21 | 334.30 | 250.04 |
| Non-current Liabilities-Total | 47.34 | 71.24 | 15.43 |
| Total Liabilities | 429.55 | 405.54 | 265.47 |
| Stockholder's Equity | |||
| Share Capital | 800.91 | 795.30 | 788.02 |
| Retained Profits | 162.43 | 38.99 | -9.62 |
| Minority Interests | 2.68 | 4.69 | 6.98 |
| Total Owners' Equity | 966.02 | 838.98 | 785.38 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 141.38 | 46.14 | 96.06 |
| Net Cash Flows-Investing | -163.18 | -275.71 | -210.31 |
| Net Cash Flows-Financing | 39.50 | 98.59 | 284.48 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 诺泰投资 | 20.00 | 12.51% |
| 赵德毅 | 13.41 | 8.39% |
| 赵德中 | 13.41 | 8.39% |
| 五星生物 | 10.31 | 6.45% |
| 伏隆贸易 | 9.51 | 5.95% |
| 鹏亭贸易 | 9.51 | 5.95% |
| 宇信管理 | 8.90 | 5.57% |
| 上将管理 | 8.81 | 5.51% |
| 方东晖 | 7.50 | 4.69% |
| 吉林敖东创新产业基金管理中心（有限合伙） | 5.28 | 3.30% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.